Altre lingue Longeveron Inc.

Azioni

LGVN

US54303L2034

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
1,74 ^USD	+1,75%		+1,16%	-87,21%

08/04	I migliori guadagni del mercato premarket	MT
20/03	Longeveron effettuerà un frazionamento azionario inverso 1 per 10	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Longeveron Files Prospectus for Secondary Offering	30/04
Longeveron to Present at the Planet MicroCap Showcase	25/04
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering	18/04
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds	17/04
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation	16/04
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)	15/04
Top Premarket Gainers	15/04
Longeveron Announces Closing of $5.2 Million Public Offering	11/04
Longeveron Announces Pricing of $5.25 Million Public Offering	08/04
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals	08/04
Top Premarket Gainers	08/04
Longeveron to Effect 1-for-10 Reverse Stock Split	20/03
Longeveron Announces 1-for-10 Reverse Stock Split	19/03
Longeveron Reports Year-End 2023 Results and Provides Corporate Update	27/02
Longeveron Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024	21/02
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™	29/01
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind Its Lead Investigation Product Lomecel-B	29/01
Longeveron Closes $2.4 Million Offering	22/12
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	21/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Longeveron Inc.

Azioni

LGVN

US54303L2034

Altre lingue

Filtri